STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMVT
  4. [Form 4] Immunovant, Inc. Insider Trading Activity

Immunovant (IMVT) grants director Frank Torti RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunovant, Inc. director Frank Torti reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 88,325 shares of common stock at an exercise price of $24.61 per share, expiring in 2036. He was also granted 174,189 restricted stock units (RSUs), each representing one share of common stock upon vesting. Both the options and RSUs vest in substantially equal quarterly installments over two years starting from April 1, 2026, contingent on his continuous service. Following the common stock award, he directly holds 1,009,228 shares of Immunovant common stock.

Positive

  • None.

Negative

  • None.
Insider Torti Frank
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 88,325 $0.00 --
Grant/Award Common Stock 174,189 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 88,325 shares (Direct); Common Stock — 1,009,228 shares (Direct)
Footnotes (1)
  1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. These options were granted pursuant to the Plan. The shares underlying the options will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.
RSU grant 174,189 units Each unit represents one share of common stock
Option grant size 88,325 shares Stock options granted April 7, 2026
Option exercise price $24.61 per share Stock option exercise price
Option expiration April 7, 2036 Stock option expiration date
Post-award holdings 1,009,228 shares Common stock held directly after grant
Vesting period 2 years Quarterly vesting from April 1, 2026
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")."
Rule 409A financial
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer as of such date."
stock option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Torti Frank
(Last)(First)(Middle)
C/O IMMUNOVANT, INC,
1000 PARK FORTY PLAZA, SUITE 210
(Street)
DURHAM NORTH CAROLINA 27713
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/07/2026A174,189(1)A$01,009,228D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$24.6104/07/2026A88,325 (2)04/07/2036Common Stock88,325$088,325D
Explanation of Responses:
1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
2. These options were granted pursuant to the Plan. The shares underlying the options will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.
Remarks:
/s/ Tiago Girao, attorney-in-fact for Frank Torti04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Immunovant (IMVT) grant to director Frank Torti?

Immunovant granted director Frank Torti stock options for 88,325 shares at a $24.61 exercise price and 174,189 restricted stock units. Both awards are part of his equity compensation and relate to Immunovant common stock.

How do Frank Torti’s new Immunovant (IMVT) RSUs vest?

Frank Torti’s 174,189 RSUs vest in substantially equal quarterly installments over two years starting April 1, 2026. Vesting is conditioned on his continuous service with Immunovant, and each unit converts into one share of common stock at settlement.

What are the terms of Frank Torti’s Immunovant (IMVT) stock options?

Torti’s options cover 88,325 Immunovant shares at a $24.61 exercise price and expire in 2036. The underlying shares vest in equal quarterly installments over two years from April 1, 2026, subject to his continued service to the company.

How many Immunovant (IMVT) shares does Frank Torti own after these awards?

After the reported common stock award, Frank Torti directly owns 1,009,228 shares of Immunovant common stock. This figure reflects his holdings following the April 7, 2026 grant reported in the Form 4 filing.

Can Frank Torti defer settlement of his Immunovant (IMVT) RSUs?

Yes. The filing states Torti may elect to defer settlement of his RSUs upon vesting, subject to Rule 409A requirements. This means he can choose to receive the underlying shares at a later date under compliant deferral arrangements.

When do Frank Torti’s Immunovant (IMVT) equity awards start vesting?

Both the RSUs and option awards begin vesting based on a schedule measured from April 1, 2026. They vest in substantially equal quarterly installments over two years, assuming Torti continues to provide service to Immunovant.